Conference Menu 

Overview
Register
Hotel & Travel
Sponsor & Exhibit
Posters
Podcast
Press Pass
Request Information
Archives 



Official Media Partner:

Bio-IT-

Word 


Lead Sponsoring Publications:

Gen 

nature 

The Scientist 

Science AAAS 


Sponsoring Publications:

Drug Discovery News 

Insight Pharma Reports 

 


Web Partner:

LabRootsLogo 

Pharmcast 

Biospace 

einnews 

GenomeWeb 


Cancer Diagnosis at the Crossroads: Precision Medicine Driving Change


Tumor collections provide insight into the great variability of cancer, its progression and its response to treatment. Patient xenografts and cell models (PDX) allow researchers to link and integrate information and determine personal variations in cancer molecular profiles. The recent advancements in high-throughput genomics, proteomics and other -omics platforms allow profiling of large numbers of cancer analytes in a single assay. Thus, knowledge of these altered molecular landscapes offers great promise for developing molecular tests to improve cancer diagnosis and optimize treatment. Cambridge Healthtech Institute’s Inaugural Cancer Diagnosis at the Crossroads: Precision Medicine Driving Change convenes international oncology experts in the fields of tumor biospecimen research, PDX models, molecular diagnostics/prognostics and pharmacogenomics.

PLENARY KEYNOTE SESSION
It Takes a Village: Defining Precision Medicine
 

Northwest BioTrust: Consented Specimens, Medical Data and Patient Registry

John T. Slattery, Ph.D., Vice Dean, Research and Graduate Education, School of Medicine; Professor, Pharmacology and Medicine, University of Washington School of Medicine

Integrating the Principles of Preventative and Personalized Care to Advance Wellness

Nathan D. Price, Ph.D., Associate Director, Institute for Systems Biology

My Avatars for Kids

James M. Olson, M.D., Ph.D., Member, Clinical Research Division, Fred Hutchinson Cancer Research Center; Professor, Pediatric Hematology and Oncology, University of Washington; Attending Physician, Seattle Children’s Hospital; Founder, Presage Biosciences

The National Biomarkers Development Alliance (NBDA): Advancing Biomarkers Development for Precision Medicine Beginning with Biospecimens

Carolyn Compton, M.D., Ph.D., CMO, National Biomarkers Development Alliance; Professor, School of Life Sciences, Arizona State University

 


The Roadmap to Precise Medicine 

Integrating Laboratory and Clinical Informatics for Next-Generation Sequencing Assays

Noah Hoffman, M.D., Ph.D., Assistant Professor, Laboratory Medicine, University of Washington

Successful Implementation of Precision Medicine in Clinical Cancer Care: The UW Experience

Colin C. Pritchard, M.D., Ph.D., Assistant Professor and Associate Director, Genetics and Solid Tumors Laboratory, Laboratory Medicine, University of Washington

 

Personalized Genomics: Platforms and Pathways 

Glycan “Node” Analysis for Detecting and Monitoring Cancer

Chad R. Borges, Ph.D., Assistant Professor, Chemistry and Biochemistry, The Biodesign Institute – Center for Personalized Diagnostics, Arizona State University

Novel Technologies Enabling Exploratory Biomarker Analysis in the Clinic

Rajiv Raja, Ph.D., Group Leader, Clinical Assays and Technologies Group, Oncology Biomarker Development, Genentech, Inc.

Integrative Genomic Analysis of Gastric Cancer

Kai Wang, Ph.D., Principal Scientist, Oncology Research Unit, Pfizer, Inc.

Development and Validation of a Clinical Trial Patient Stratification Assay that Interrogates 27 Mutation Sites in MAPK Pathway Genes

Ken C.N. Chang, Ph.D., Clinical Assay Development and Outsourcing Lead, Clinical Biomarkers and Diagnostics, Merck & Co., Inc.

An Inducible, Isogenic Cancer Cell Line System for Targeting the State of Mismatch Repair Deficiency

Julie Bailis, Ph.D., Senior Scientist, Oncology Research, Amgen, Inc.

 

Patient-Derived Models (PDX) as Translational Platforms for Oncology Therapies 

Featured Presentation

Development of New Therapeutic Agents Targeting Key Cancer Stem Cell Pathways

Timothy Hoey, Ph.D., Senior Vice President, Cancer Biology, OncoMed Pharmaceuticals, Inc.

Next-Generation Patient-Derived Prostate Cancer Xenograft Models

Yuzhuo Wang, Ph.D., Associate Professor, Urologic Sciences, University of British Columbia

Understanding Cancer Stem Cells in Human Melanoma Using a Patient-Derived Tumor Xenograft Model

Mayumi Fujita, M.D., Ph.D., Associate Professor, University of Colorado Denver School of Medicine

Fluorescently Labeled Chimeric Anti-CEA Antibody Improves Detection and Resection of Gastrointestinal Cancers in Patient-Derived Orthotopic Xenograft (PDOX) Nude Mouse Models

Michael Bouvet, M.D., Professor, Surgery; Director, Endocrine Surgery; Co-Director, GI Cancer Unit, Moores Cancer Center, University of California, San Diego

Molecular Characterization of Patient-Derived Human Pancreatic Tumor Xenograft Models for Preclinical and Translational Development of Cancer Therapeutics

Pia Challita-Eid, Director, Molecular Biology, Agensys, Inc. (tentative)


BNKconjunctionLogo 


By Series:
By Region:


Conference
& Course Catalog

CHI Catalog 


Short Course DVDs